Insider Selling: Establishment Labs (NASDAQ:ESTA) Director Sells 67,249 Shares of Stock
by Renee Jackson · The Cerbat GemEstablishment Labs Holdings Inc. (NASDAQ:ESTA – Get Free Report) Director Quiros Juan Jose Chacon sold 67,249 shares of the company’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $70.78, for a total transaction of $4,759,884.22. Following the completion of the sale, the director directly owned 1,040,255 shares in the company, valued at approximately $73,629,248.90. The trade was a 6.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Quiros Juan Jose Chacon also recently made the following trade(s):
- On Monday, May 4th, Quiros Juan Jose Chacon sold 7,751 shares of Establishment Labs stock. The stock was sold at an average price of $70.48, for a total transaction of $546,290.48.
- On Monday, April 27th, Quiros Juan Jose Chacon sold 2,180 shares of Establishment Labs stock. The stock was sold at an average price of $66.26, for a total transaction of $144,446.80.
- On Friday, April 24th, Quiros Juan Jose Chacon sold 30,178 shares of Establishment Labs stock. The shares were sold at an average price of $65.78, for a total value of $1,985,108.84.
- On Thursday, April 23rd, Quiros Juan Jose Chacon sold 42,642 shares of Establishment Labs stock. The shares were sold at an average price of $65.43, for a total value of $2,790,066.06.
- On Tuesday, April 14th, Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock. The stock was sold at an average price of $65.23, for a total value of $2,446,125.00.
- On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The stock was sold at an average price of $60.08, for a total value of $214,786.00.
- On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The shares were sold at an average price of $60.39, for a total value of $2,048,730.75.
Establishment Labs Price Performance
Shares of Establishment Labs stock traded up $0.01 on Monday, reaching $70.24. The company’s stock had a trading volume of 674,327 shares, compared to its average volume of 499,774. The company has a quick ratio of 2.00, a current ratio of 3.04 and a debt-to-equity ratio of 10.51. The company has a market capitalization of $2.06 billion, a P/E ratio of -40.37 and a beta of 1.12. The stock has a 50-day moving average price of $65.53 and a 200-day moving average price of $66.03. Establishment Labs Holdings Inc. has a 52-week low of $32.25 and a 52-week high of $83.31.
Establishment Labs (NASDAQ:ESTA – Get Free Report) last announced its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.13. The firm had revenue of $64.62 million for the quarter, compared to analyst estimates of $63.80 million. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The business’s revenue was up 45.2% on a year-over-year basis. During the same quarter last year, the firm posted ($1.19) EPS. Analysts expect that Establishment Labs Holdings Inc. will post -0.86 EPS for the current year.
Analyst Upgrades and Downgrades
ESTA has been the topic of several research analyst reports. Needham & Company LLC lifted their target price on shares of Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research report on Friday, March 27th. Canaccord Genuity Group upped their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Stephens upped their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Finally, BTIG Research restated a “buy” rating and set a $88.00 price target on shares of Establishment Labs in a research report on Wednesday, April 29th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $86.86.
Get Our Latest Stock Analysis on ESTA
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. Tejara Capital Ltd raised its holdings in Establishment Labs by 31.2% in the 3rd quarter. Tejara Capital Ltd now owns 102,494 shares of the company’s stock valued at $4,201,000 after acquiring an additional 24,386 shares during the last quarter. Woodson Capital Management LP raised its holdings in Establishment Labs by 113.3% in the 3rd quarter. Woodson Capital Management LP now owns 480,000 shares of the company’s stock valued at $19,675,000 after acquiring an additional 255,000 shares during the last quarter. William Blair Investment Management LLC raised its holdings in Establishment Labs by 17.6% in the 3rd quarter. William Blair Investment Management LLC now owns 1,017,543 shares of the company’s stock valued at $41,709,000 after acquiring an additional 152,299 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in Establishment Labs by 59.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 115,876 shares of the company’s stock valued at $8,445,000 after acquiring an additional 43,164 shares during the last quarter. Finally, Bamco Inc. NY raised its holdings in Establishment Labs by 30.2% in the 3rd quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock valued at $48,443,000 after acquiring an additional 274,287 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.
Establishment Labs Company Profile
Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.
The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.